Lv4
430 积分 2022-12-27 加入
Identification of a small-molecule Tim-3 inhibitor to potentiate T cell–mediated antitumor immunotherapy in preclinical mouse models
1小时前
待确认
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
1小时前
已完结
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
1小时前
已完结
Hyperactive DCs redirect aged anti-tumor immunity
1小时前
求助中
Beyond T cell exhaustion: TIM-3 regulation of myeloid cells
1小时前
已完结
Tumour burden and efficacy of immune-checkpoint inhibitors
3小时前
已完结
Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study
3小时前
已完结
Abatacept in B7-1–Positive Proteinuric Kidney Disease
3小时前
已关闭
A decade of immune-checkpoint inhibitors in cancer therapy
3小时前
已关闭
Immune-related adverse events of checkpoint inhibitors
3小时前
已完结
皖公网安备34019202002308
